Decron Properties buys 391 Thousand Oaks apartment units for $126.5 million
Los Angeles-based developer Decron Properties acquired a 391-unit multifamily apartment portfolio in Thousand Oaks for $126.5 million. The deal with Prometheus Real Estate Group included the 249-unit Los Robles Apartments and the 142-unit Marlowe Apartments located about a mile apart near Moorpark Road. The complexes feature swimming pools, clubhouses, fitness centers and large amounts of Read More →
Amgen Tour of California to include Thousand Oaks to Santa Barbara leg
Organizers of the 12th annual Amgen Tour of California bicycle race announced the full route on Jan. 28. The 2016 race will run 782.7 miles from San Diego to Sacramento from May 15 to May 22. This year will also be just the second time out of 11 previous races that the route runs south Read More →
Amgen revenues up 8 percent in 2015
Despite increased competition from biosimilars and blockbuster mergers by its rivals, Amgen revenues rose 8 percent to $21.67 billion in 2015 from $20.06 billion in 2014. Thousand Oaks-based biotech giant Amgen released its fourth-quarter earnings after markets closed on Jan. 28. Quarterly revenues were also up 4 percent to $5.54 billion in 2015 from $5.33 Read More →
Ceres awarded patent in Australia for trait that increases crop yields
Thousand Oaks-based Ceres Inc., an ag-biotech company, was awarded a patent in Australia for a trait that allows growers to increase yields without increasing crop inputs like fertilizer. The patent extends intellectual property protection to the Australian market of a key gene that Ceres has licensed to a multinational crop developer. It covers uses of Read More →
Tri-Counties race to control marijuana
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Ceres still raising money despite losses
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen drug Kyprolis gets another FDA approval
Amgen scored another victory for its breakthrough multiple myeloma drug on Jan. 21. The Thousand Oaks-based biotech giant hit it big when the Food and Drug Administration approved revolutionary multiple myeloma drug Kyprolis for treatments with Kyprolis in combination with another drug. The FDA also approved Kyprolis to treat patients on its own for those Read More →
